$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹726
INTRODUCTION PIRFETAB 801MG contains Pirfenidone which belongs to the group of medicines called Anti-fibrotics or Anti-inflammatory agents. It is used in the treatment of mild to moderate Idiopathic pulmonary fibrosis in adults. Idiopathic pulmonary fibrosis is a condition in which the tissues...
PIRFETAB 801MG contains Pirfenidone which belongs to the group of medicines called Anti-fibrotics or Anti-inflammatory agents. It is used in the treatment of mild to moderate Idiopathic pulmonary fibrosis in adults. Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs (alveoli) become swollen and scarred over time and making it difficult to breathe. This makes it hard for the lungs to work properly.
PIRFETAB 801MG is not recommended for use in patients with severe or end-stage liver or kidney disease. Before taking PIRFETAB 801MG inform your doctor if you have mild to moderate liver disease, kidney problems or photosensitivity reactions. PIRFETAB 801MG is not recommended for use in pregnant women unless advised by your doctor. It is not known whether PIRFETAB 801MG passes into breast milk, hence consult your doctor before taking this medicine.
PIRFETAB 801MG is not recommended for use in children and adolescents below 18 years of age. PIRFETAB 801MG should be used with caution in elderly patients aged 65 years or above. Contact your doctor before taking this medicine. Avoid smoking while using PIRFETAB 801MG as it reduces the effect of this medicine. Also, avoid drinking grapefruit juice as it may lead to unwanted effects.
The most common side effects of taking PIRFETAB 801MG are nausea, stomach problems such as acid reflux, vomiting, constipation, diarrhoea, indigestion or stomach upset, weight loss, decreased appetite , tiredness, dizziness, headache. Consult your doctor if any of the above side effects worsen.
PIRFETAB 801MG works by exhibiting anti-inflammatory, antioxidant and antifibrotic properties that suppress the factors (transforming growth factor -β (TGF-β)) causing scarring and swelling of the tissues. As a result, it treats and controls the fibrosis of the tissues resulting in improving lung function.
Take PIRFETAB 801MG as advised by your physician. Swallow the medicine with a glass of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
Stop taking PIRFETAB 801MG and contact your doctor immediately if you experience any of the following side effects:
Headache:
Drink ample amount of water. Get adequate rest. Try to be relaxed and stress free. Apply a pain-relieving balm on the forehead if necessary. Contact your doctor if the symptom does not improve.
Nausea and Vomiting:
Take the PIRFETAB 801MG, with or just after a meal. Stick to simple meals. Avoid eating oily, fried or spicy foods. Contact your doctor if the symptom does not improve.
Diarrhoea:
Drink lot of fluids, such as water or fruit juices to keep yourself hydrated. Do not take any medicine on your own to treat diarrhoea. Contact your doctor if the symptom does not improve.
Constipation:
Take fiber rich foods in your diet such as fresh fruits, vegetables and whole grain cereals, and drink plenty of fluids. Exercise more regularly and stay active. Contact your doctor if the symptom does not improve.
Decreased appetite:
Eat when you feel hungry. Eat smaller meals frequently than usual. Snack only when you're hungry. Eat a nutritious snack which is rich in calories and protein, such as dried fruit and nuts. Contact your doctor if the symptom does not improve.
PIRFETAB 801MG is not recommended for use if you are pregnant, planning to become pregnant or think you might be pregnant as the potential risks to the unborn child are unknown. Consult your doctor before taking PIRFETAB 801MG.
It is not known whether PIRFETAB 801MG pass through the breast milk, hence, consult your doctor before taking PIRFETAB 801MG.
Do not drive or operate any machines if you feel dizzy or tired after taking PIRFETAB 801MG.
PIRFETAB 801MG is not recommended for use in patients with severe or end-stage kidney disease (requiring dialysis). It should be used with caution in patients with mild to moderate kidney problems. Consult your doctor before taking PIRFETAB 801MG.
PIRFETAB 801MG is not recommended for use in patients with severe or end-stage liver disease. It should be used with caution in patients with mild to moderate liver disease. Consult your doctor before taking PIRFETAB 801MG.
Do not take PIRFETAB 801MG if you are allergic to Pirfenidone.
Before taking PIRFETAB 801MG, inform your doctor if you:
Use in pediatrics:
PIRFETAB 801MG is not recommended for use in children and adolescents under 18 years of age. Contact child’s doctor for advice.
Use in geriatrics:
PIRFETAB 801MG should be taken with caution in elderly patients (above 65 years of age) Your doctor will decide the dose, duration of the treatment and its frequency for you depending on the severity of your existing condition and other comorbid diseases.
A. Drug-Drug Interaction:
Before taking PIRFETAB 801MG, inform your doctor if you are taking any of the following medicines:
B. Drug - Food interaction:
Avoid drinking grapefruit juice while taking PIRFETAB 801MG as it may lead to unwanted effects. Consult your doctor before taking PIRFETAB 801MG.
Overdosage:
If you or anyone else accidentally take too much of PIRFETAB 801MG, consult your doctor immediately or visit the nearby hospital.
| Drug | : | Pirfenidone |
| Pharmacological Category | : | Anti-fibrotics or Anti-inflammatory agents |
| Therapeutic Indication | : | Mild to moderate Idiopathic Pulmonary Fibrosis |
| Dosage Forms | : | Tablet |
Can PIRFETAB 801MG be used for treating lung disease?
Yes, PIRFETAB 801MG is used to treat mild to moderate idiopathic pulmonary fibrosis (condition in which the lungs become scarred and breathing becomes increasingly difficult) in adults above 18 years of age. Consult your doctor before taking PIRFETAB 801MG.
Does PIRFETAB 801MG cause liver damage?
Yes, PIRFETAB 801MG may cause liver damage. Stop taking PIRFETAB 801MG and contact your doctor if you experience any unusual symptoms like yellowish discolouration of skin and white of the eyes, dark urine, itching of the skin, pain on the upper right side of the abdomen, loss of appetite, bleeding or bruising more easily and tiredness. Consult your doctor before taking PIRFETAB 801MG.
Does PIRFETAB 801MG cause dizziness?
Yes, PIRFETAB 801MG may cause dizziness. To manage this effect, try to rest and relax and get enough sleep. Avoid driving or operating any machines while you are feeling dizzy. Do not consume alcohol, as it can aggravate your dizziness. Consult your doctor if the symptom does not improve.
Is PIRFETAB 801MG a steroid medicine?
No, PIRFETAB 801MG is not a steroid medication. It is used to treat mild to moderate idiopathic pulmonary fibrosis (IPF) in adults. It causes scarring and swelling of the lung tissue resulting in breathing difficulties. This medicine helps to reduce the symptoms of the disease and make you breathe better.
Is PIRFETAB 801MG safe to use during pregnancy?
PIRFETAB 801MG is not recommended for use if you are pregnant, planning to become pregnant or think you might be pregnant as the potential risks to the unborn child are unknown. Consult your doctor before taking PIRFETAB 801MG.
1. Laurance Brunton. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. Chemotherapy of neoplastic diseases 12th Edition, 2011. Page - 1718.
2. Genentech, Inc. Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) (ASCEND). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised in April 2017] [Accessed on 18th June 2022] https://clinicaltrials.gov/ct2/show/NCT01366209
3. Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre, and Talmadge E. King, Jr. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. NIH. National Library of Medicine, National center for biotechnology information. January 2016. [Accessed on 18th June 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697914/
4. Roche Products Limited. Electronic Medicines Compendium (EMC). [Revised in February 2022] [Accessed on 18th June 2022] https://www.medicines.org.uk/emc/files/pil.2731.pdf
5. InterMune, Inc. U.S. Food & Drug Administration. [Revised in October 2014] [Accessed on 18th June 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
6. Roche Pharma AG. European Medical Agency (EMA). [Revised in September 2015] [Accessed on 18th June 2022] https://www.ema.europa.eu/en/documents/product-information/esbriet-epar-product-information_en.pdf
7. Hoffmann-La Roche Limited. Pirfenidone. [Revised in August 2021] [Accessed on 18th June 2022] https://www.rochecanada.com/PMs/Esbriet/Esbriet_PM_E.pdf